TRBV22OR9-2

Across TCGA pan-cancer cohorts, TRBV22OR9-2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated TRBV22OR9-2 data layer.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TRBV22OR9-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV22OR9-2 expression acts as an unfavorable survival marker.

CESC, PAAD, and BLCA are the cancer types where TRBV22OR9-2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Tertile	II,III,IV	0.165	0.765	<.001	126	view →
PAAD	DFS	Tertile	II,III,IV	0.170	0.441	.005	36	view →
BLCA	OS	Tertile	All	0.219	0.691	.006	27	view →
KIRC	OS	Tertile	All	0.367	0.633	.009	24	view →
LUSC	DFS	Tertile	III,IV	0.010	0.754	<.001	24	view →
KIRP	OS	Tertile	All	0.181	0.704	.009	24	view →
DLBC	DFS	Tertile	IV	0.120	0.683	.001	18	view →
ESCA	DFS	Tertile	III,IV	0.172	0.447	.046	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TRBV22OR9-2–CESC (OS)

Open the CESC breakdown →